Ensoma

BioTech Scout

Discover the most promising early-stage companies in life sciences, scouted by BioPharmaTrend. Follow company news and important business events.

back to Directory

Ensoma

Website
https://ensoma.com/

Founded
2021

Patents
5

Publications
5

Technologies

CRISPR Startups Gene Therapy Startups Virotherapy

Their main innovation relates to Ensoma Engine, an ingenious vector engineered specifically to deliver genetic material directly to hematopoietic stem-cells or other cells arising from them. This would erase the need to collect stem cells from the patient or use chemotherapy for myeloablative conditioning and potentially yield the single injection therapy. If successful, this would dramatically simplify the storage, logistics and increase the availability of this therapy worldwide.

viral vector gene editing genomic medicine

Posts Mentioning This Company

7 Biotechs Fighting Rare Diseases With Gene-Editing Tech

As of now, only 5% of so-called rare diseases (orphan diseases) have an FDA-approved treatment available to patients. Rare diseases are defined as those affecting fewer than 1 in 200.000 people with almost 80% of all rare diseases being of genetic nature. With recent progress in gene-editing technologies, including breakthroughs …

R&D Platform

Our ingeniously engineered Engenious™ vectors are the most advanced of gene-modifying vectors.
The foundation of Ensoma’s next-generation approach is our ingeniously engineered Engenious™ vectors. Also known as helper-dependent adenoviral vectors or “gutless vectors,” our Engenious™ vectors are designed to deliver a diverse range of gene modification technologies – including those that require a high level of packaging capacity – directly to blood stem cells, also known as hematopoietic stem cells (HSCs), or the various types of cells that arise from these cells, such as T cells, B cells and myeloid cells, without the need for stem cell collection or prior conditioning (e.g. chemotherapy).